You are viewing the site in preview mode

Skip to main content

Table 2 HRs and 95%CIs for the associations between, clinical depression, antidepressant use, and breast cancer risk

From: Depression, antidepressant use, and breast cancer incidence in the Sister Study cohort

 

Clinical Depression

Antidepressant Use

 

Exposed/Non-Exposed Cases

HR (95% CI)

Exposed/Non-Exposed Cases

HR (95% CI)

Overalla

917/2982

0.98 (0.91, 1.06)

790/3109

0.92 (0.85, 1.00)

DCIS

190/630

0.99 (0.84, 1.17)

158/662

0.89 (0.74, 1.06)

Invasive

724/2347

0.98 (0.90, 1.07)

630/2441

0.93 (0.85, 1.02)

ER positiveb

549/1743

1.00 (0.91, 1.10)

490/1802

0.98 (0.88, 1.08)

ER negativeb

81/293

0.84 (0.66, 1.08)

69/305

0.78 (0.60, 1.03)

Overall Premenopausal

126/464

0.99 (0.81, 1.21)

118/472

1.04 (0.85, 1.28)

Overall Postmenopausal

791/2518

0.98 (0.90, 1.06)

672/2637

0.90 (0.83, 0.99)

Invasive Premenopausal

96/362

0.95 (0.76, 1.19)

89/369

0.99 (0.78, 1.26)

Invasive Postmenopausal

628/1985

0.98 (0.90, 1.08)

541/2072

0.92 (0.84, 1.02)

  1. Abbreviations DCIS ductal carcinoma in situ, ER estrogen receptor
  2. All models were adjusted for age, race/ethnicity, family history of breast cancer, age at menarche, breastfeeding history, parity, menopausal status, any hormonal contraceptive use, hormone therapy type, oophorectomy status, BMI, physical activity level, smoking status, alcohol intake, mammogram in prior 2 years, alternative healthy eating index score, education level, annual household income per person, age at first birth, and family history of breast cancer
  3. Clinical Depression models (excluding by menopausal status) also adjusted for interaction between BMI and menopausal status at baseline
  4. Reference group: For the clinical depression models (women without a clinical depression diagnosis); for the antidepressant use models (non-users of antidepressants)
  5. aIncludes Invasive and DCIS breast cancer
  6. bn = 23 were excluded due to unknown ER status